RxDoctor Payments Data

Geoffrey Wilson, MD

Cardiovascular Disease · Portland, ORNPI 1336185438

Payments from drug & device makers

$2,940in general payments, 2019–2025

Across 26 payments — averaging $113.06 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Abbott$1K
  • Edwards Lifesciences$1K
  • Medtronic$167
  • AstraZeneca$127
  • Boehringer Ingelheim$125
  • Amgen$35
  • plus $40 from 2 others

What the payments were for

  • Travel & lodging$2,00368%
  • Food & beverage$93732%

General payments by program year

19
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Abbott12$1,264
Edwards Lifesciences6$1,182
Medtronic3$167
AstraZeneca1$127
Boehringer Ingelheim1$125
Amgen1$35
Pfizer1$20
Novartis1$20

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,940 in reported general payments places this provider in the 65th percentile of 198 cardiovascular disease providers in Oregon.

See all cardiovascular disease providers in Oregon

Medicare billing

Part B allowed, 2024
$125,837
Medicare patients
1,964
Services billed
3,051

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban308$430,612
EntrestoSacubitril/Valsartan112$144,847
JardianceEmpagliflozin144$143,648
FarxigaDapagliflozin Propanediol54$66,918
XareltoRivaroxaban50$61,963
Repatha SureclickEvolocumab24$24,715
Atorvastatin Calcium377$4,976
Metoprolol Succinate362$4,807
Potassium Chloride115$3,196
Losartan Potassium214$2,683
Rosuvastatin Calcium185$2,443
Isosorbide Mononitrate ErIsosorbide Mononitrate107$1,861
Torsemide60$1,579
Amlodipine Besylate194$1,562
Furosemide182$1,426

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$20$430,612308 claims
NovartisEntresto$20$144,847112 claims
Boehringer IngelheimJardiance$125$143,648144 claims
AstraZenecaFarxiga$127$66,91854 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 198 cardiovascular disease providers in Oregon.

Other cardiovascular disease in Portland

See the full list for Oregon

Where these figures come from

Is this you, or does something look wrong? →